Near future
No Result
View All Result
23 September 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

Tirzepatide, remarkable tests: average weight loss of 24kg. Goodbye obesity?

Patients with obesity from a large clinical trial lost an average of 24kg when treated with the highest dose of a new hunger-blocking drug

May 6, 2022
Gianluca RiccioGianluca Riccio
⚪ 3 minutes
Share108Pin25Tweet67SendShare19ShareShare13
61B51597 103B 441B 8445 532A1CEA5916

READ IN:

Tirzepatide has shown incredible results in clinical trials. On average, patients who received it as a treatment lost 24 kg during the study period. It can be a giant step forward in the treatment of obesity, helping millions of people around the world lose weight.

A drug instead of surgery?

In fact, the weight loss achieved in the tests is surprising - it is the equivalent of a bariatric surgery. Is it plausible that tirzepatide could replace surgery in the treatment of obesity in the near future?

The drug combines synthetic imitations of two hormones known as GLP-1 e GIP, that our body releases naturally when we eat, to provide us with the feeling of satiety.

Tirzepatide obesity
A model of the GLP-1 hormone, which Tirzepatide "mimics".

In an advanced clinical trial, over 2.500 individuals in nine countries received weekly injections of low, medium, or high-dose tirzepatide (or a placebo) for 72 weeks.

The article continues after the related links

New cholesterol-lowering drug also cuts obesity in tests on mice

Modern Foods: The Protein Deception Has Produced an Obesity Epidemic

Patients who received the highest dose had an average weight loss of 24 kilograms. Almost a quarter of the body weight. In comparison, participants taking the placebo lost only 2 kilograms on average. The results have been announced from the US pharmaceutical giant Lilly, which is developing the drug.

Obesity is a fight without quarter

The pharmacological approach to obesity does not start today. As early as June 2021, the American FDA had approved another drug called semaglutide which contains only the GLP-1 hormone, without the addition of GIP. The results? Good, with an average weight loss of 15%, but the newly developed drug is much more advanced.

For both drugs, however, there are contraindications: side effects such as nausea, vomiting, diarrhea and constipation (which seem to get worse at higher doses). The experience gained with semaglutide suggest that starting with low doses and gradually increasing them can avoid these side effects.

The advantages are undoubted

To be clear: these obesity drugs can be discontinued, bariatric surgery cannot. You can never have a normal or large meal again, even on a special occasion. Of course, it is also true that surgery is done only once, while these drugs must be taken continuously.

Let's put it this way: it is imperative that people have many options for acting on obesity. Now another 104 weeks of monitoring (to determine if tirzepatide also prevents type 2 diabetes, but more on that) and then Lilly will ask for approval of the drug.

Obesity is a global problem and we need to more effective treatments than ever. Tirzepatide could be the decisive step.

Tags: drugsobesity

Latest news

  • The bizarre AI that translates the language of chickens
  • Jeddah Tower, construction site of the one kilometer high skyscraper reopens
  • Spider silk from modified silkworms: stronger than Kevlar and 100% natural
  • VIR-1388, HIV vaccine being tested in the USA and South Africa
  • MOWT, innovative floating hydroelectric for slow-flowing waters
  • CRAFT, what stage is the Chinese project to build an artificial Sun?
  • Remote work, halved emissions
  • Shipping pallets in the digital age: how the Internet has revolutionized the logistics landscape
  • BMW 7 Series Protection: the sedan that defies grenades and flamethrowers
  • First nerve networks 3D printed with bioink


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+